CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study

Core Insights - Corcept Therapeutics' shares increased by 13.7% following the announcement that the phase III ROSELLA study met its overall survival primary endpoint for relacorilant in combination with nab-paclitaxel in treating platinum-resistant ovarian cancer [1] Study Results - The ROSELLA study demonstrated a 35% reduction in the risk of death for patients treated with relacorilant plus nab-paclitaxel compared to those receiving nab-paclitaxel alone [2] - Patients receiving the combination therapy achieved a median overall survival (OS) of 16 months, compared to 11.9 months for those on nab-paclitaxel alone [3] - The combination treatment was well tolerated, with a safety profile consistent with existing data, providing clinical benefits without increasing safety risks [3] Regulatory Developments - The FDA accepted the new drug application (NDA) for relacorilant in combination with nab-paclitaxel, with a decision expected on July 11, 2026 [6][9] - Corcept submitted a marketing authorization application to the European Medicines Agency for relacorilant, with a decision anticipated later in 2026 [9] Market Context - Corcept's shares have declined by 40% over the past six months, contrasting with a 2.9% decline in the industry [4] - The company previously faced a setback when the FDA issued a complete response letter regarding the NDA for relacorilant in treating hypercortisolism, which negatively impacted investor sentiment [11][12] Financial Performance - Korlym, Corcept's sole-marketed drug for Cushing's syndrome, generated sales of $559.3 million in the first nine months of 2025, reflecting a year-over-year increase of approximately 13.4% [13]